Understanding how T-cell receptors influence T-cell lymphoma progression
Official title: THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS
Funded at University of Michigan at Ann Arbor · NIH-11014942 · Data updated 2026-11-12
This study is looking at how certain immune cells called T-cells behave in T-cell lymphoma, especially how they interact with other cells in the tumor environment, to find new ways to improve treatment options for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $320,391 |
| NIH project number | 5R37CA233476-07 |
| Project ID | NIH-11014942 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with T-cell lymphoma who are experiencing disease progression or chemotherapy resistance.
✕Less likely to help
Patients with other types of lymphoma or those who are not currently undergoing treatment for T-cell lymphoma may not benefit from this research.
What this research studies
This research investigates the role of T-cell receptors in T-cell lymphoma (TCL) and how they contribute to the disease's progression and resistance to chemotherapy. The study focuses on the tumor microenvironment, particularly the interaction between malignant T cells and antigen-presenting cells, such as lymphoma-associated macrophages. By examining the mechanisms of T-cell activation and the role of specific transcription factors like GATA-3, the research aims to uncover new insights into TCL and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with T-cell lymphoma, potentially overcoming chemotherapy resistance.
How similar studies have gone: Previous research has shown promising results in understanding the role of T-cell receptors in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wilcox, Ryan a — University of Michigan at Ann Arbor
- Study coordinator: Wilcox, Ryan a
Related research
Other NIH-funded projects on the same topics.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial
A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
How a rare intestinal T‑cell lymphoma begins
This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.
-
CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.